Anti-Mouse VEGFR-2 Monoclonal Antibodies

Background

Our recombinant VEGFR-2 antibodies have a part (variable regions) or complete amino acid sequences of the rat anti-mouse VEGFR-2 monoclonal antibody (hybridoma clone name or number: DC101).

PA007527.r1: In Vivo Grade Recombinant Anti-mouse VEGFR-2 Monoclonal Antibody (Clone: DC101), Rat IgG1 Kappa

The in vivo grade recombinant anti-mouse VEGFR-2 rat IgG1 monoclonal antibody was produced in mammalian cells.
Specificity: VEGFR-2.
Clone: DC101.
Isotype: rat IgG1, kappa.
Applications: Western blot, immunoprecipitation (IP), Flow Cytometry (FC), and various in vitro and in vivo functional assays.
Formulation: 0.2 μM filtered solution of 1x PBS.
Purity: >95% by SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU/mg of protein as determined by LAL method.

Shipping: The in vivo grade recombinant anti-mouse VEGFR-2 antibodies (clone of DC101) are shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

Syd Labs provides the following anti-mouse PD1 (PD-L1) and VEGFR2 monoclonal antibodies:
In vivo grade recombinant anti-mouse PD-1 monoclonal antibodies (Clone RMP1-14.1)
In vivo grade recombinant anti-mouse PD 1 monoclonal antibodies (Clone 29F.1A12.1)
In vivo grade recombinant anti-mouse PD-L1 monoclonal antibodies (Clone 10F.9G2.1)
In vivo grade recombinant anti-mouse VEGFR2 monoclonal antibodies (Clone DC101)

Syd Labs provides the following anti-mouse PD-1 / VEGFR-2 bispecific antibodies:
In vivo grade recombinant anti-mouse PD 1 / VEGFR2 bispecific antibodies (Clone RMP1-14.1 / DC101)
In vivo grade recombinant anti-mouse PD-1 / VEGFR-2 bispecific antibodies (Clone 29F.1A12.1 / DC101)

Syd Labs provides the following anti-mouse PD-L1 / VEGFR-2 bispecific antibodies:
In vivo grade recombinant anti-mouse PDL1 / VEGFR-2 bispecific antibodies (Clone 10F.9G2.1 / DC101)

References of anti-mouse VEGFR-2 antibody (Clone: DC101):

A VEGFR2?MICA bispecific antibody activates tumor-infiltrating lymphocytes and exhibits potent anti-tumor efficacy in mice
Xu, Y., et al. Mol Cancer Ther. 2024 Aug 2;23(8):1069-1082. doi: 10.1158/1535-7163.MCT-23-0564. PMID: 38791979
DC101, an anti-mouse VEGFR2 antibody, was purchased from BioXCell (West Lebanon, NH, USA). The positive control DC101 was stained with PE-conjugated goat anti-rat IgG antibody (Biolegend, USA). At the same dose level of 200 nM, the apoptosis rate of JZC00 (Fig. 3c) and JZC01 (Fig. 3d) was roughly similar. JZC01 and JZC00 possessed similar binding to those two cell lines, but little binding was seen with rMICA treatment (Fig. 2c, d). The tumor volumes were measured every 3 days, and JZC01 treatment significantly reduced tumor growth compared to controls (P < 0.01).
Tags: anti-mouse VEGFR-2 DC101; anti-mouse VEGFR-2 DC101 antibody

Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody
Park, J. A., et al. J Immunother Cancer. 2023 Apr;11(4):e006150. doi: 10.1136/jitc-2022-006150. PMID: 36990507
Anti-human VEGF (bevacizumab, BVZ) or anti-mouse VEGFR2 antibody (DC101) was used as VEGF blockade, and ex vivo armed T cells (EATs) carrying anti-GD2, anti-HER2, or anti-glypican3 (GPC3) IgG-(L)-scFv platformed BsAb were used. Mice-bearing HGSOC1 osteosarcoma PDX were treated with T cells armed ex vivo with anti-HER2-BsAb (HER2-EATs) with or without VEGF blockade using BVZ (anti-hVEGF) or DC101 (anti-mVEGFR2). Luciferase transduced T cells armed with anti-HER2-BsAb (Luc (+) HER2-EATs) were administered in combination with BVZ or with DC101 to mice bearing HGSOC1 osteosarcoma PDX. Combinations of GD2-EATs and anti-VEGF (BVZ) (G4) or anti-VEGFR2 antibody (DC101) (G5) induced high endothelial venules (HEVs) in tumors. Tumor growth inhibition was observed in 80% of mice receiving combined GD2-EATs and DC101 treatment.
Tags: anti-mouse VEGFR-2 DC101 antibody in vivo; anti-mouse VEGFR-2 DC101 in animal model

Neutralization of the induced VEGF-A potentiates the therapeutic effect of an anti-VEGFR2 antibody on gastric cancer in vivo
Kang, W., et al. Am J Cancer Res. 2021 Mar 15;11(3):879-895. PMID: 33791159
The anti-mouse VEGFR-2 antibody (DC101, 800 ?g/mouse) was administered intraperitoneally twice weekly for 3 weeks in MKN45 gastric cancer xenografts. Tumor volume was measured every 3 days using a caliper, showing significant reduction in DC101-treated groups compared to controls (P < 0.05). Combined treatment with anti-VEGF-A and DC101 reduced microvessel density by 60% in tumor sections, as assessed by CD31 staining. Serum VEGF-A levels were quantified by ELISA, showing a 45% decrease in DC101-treated mice. Kaplan-Meier analysis indicated improved survival in mice receiving dual VEGF-A/VEGFR-2 blockade.
Tags: anti-mouse VEGFR-2 DC101 antibody in animal model; anti-mouse VEGFR-2 DC101 in cancer research

Anti-VEGFR2 therapy promotes antitumor immunity in glioblastoma by enhancing dendritic cell migration
Woroniecka, K., et al. Clin Cancer Res. 2021 Dec 15;27(24):6771-6783. doi: 10.1158/1078-0432.CCR-21-1285. PMID: 34580351
Mice were treated with anti-mouse VEGFR-2 antibody (DC101, 10 mg/kg i.p.) starting 7 days post-tumor implantation to modulate the tumor microenvironment. DC101 blockade reduced VEGFR2+ pericyte coverage on vessels, as assessed by co-staining with anti-NG2 and anti-CD31 in flow cytometry. Therapeutic efficacy was validated by combining DC101 with anti-PD-1, resulting in 40% long-term survivors. Peripheral blood mononuclear cells were isolated and analyzed for VEGFR2 expression on monocytes pre- and post-treatment. Flow cytometry of brain-infiltrating leukocytes demonstrated a 3-fold increase in CD11c+ MHCII+ dendritic cells in DC101-treated tumors.
Tags: anti-mouse VEGFR-2 DC101 in mouse tumor model; function of anti-mouse VEGFR-2 DC101

Combined VEGFR2 and PD-L1 blockade in renal cell carcinoma
Manning, E. A., et al. Cancer Immunol Res. 2017 Nov;5(11):1008-1018. doi: 10.1158/2326-6066.CIR-17-0201. PMID: 29084200
Anti-mouse VEGFR-2 (DC101, 40 mg/kg i.p. weekly) was administered alone or in combination with anti-PD-L1 in RENCA syngeneic tumor models. DC101 treatment significantly reduced tumor vessel density by 55%, as confirmed by immunohistochemistry. Flow cytometry analysis showed increased infiltration of CD8+ T cells in tumors from DC101-treated mice. Combination therapy prolonged median survival by 25 days compared to single-agent treatments. Peripheral immune cells were assessed for PD-L1 expression, revealing upregulation post-DC101 administration.
Tags: bioactivity of anti-mouse VEGFR-2 DC101; anti-mouse VEGFR-2 DC101 antibody of low endotoxin

For more references about anti-mouse VEGFR-2 antibody (Clone: DC101), please contact our scientific support team with message@sydlabs.com.